APA (7th ed.) Citation

DS, A., HH, E., & TM, A. (2023). The use and safety risk of repurposed drugs for COVID-19 patients: Lessons learned utilizing the Food and Drug Administration's Adverse Event Reporting System. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 31(7), 1360. https://doi.org/10.1016/j.jsps.2023.05.023

Chicago Style (17th ed.) Citation

DS, Alsuhaibani, Edrees HH, and Alshammari TM. "The Use and Safety Risk of Repurposed Drugs for COVID-19 Patients: Lessons Learned Utilizing the Food and Drug Administration's Adverse Event Reporting System." Saudi Pharmaceutical Journal : SPJ : The Official Publication of the Saudi Pharmaceutical Society 31, no. 7 (2023): 1360. https://doi.org/10.1016/j.jsps.2023.05.023.

MLA (9th ed.) Citation

DS, Alsuhaibani, et al. "The Use and Safety Risk of Repurposed Drugs for COVID-19 Patients: Lessons Learned Utilizing the Food and Drug Administration's Adverse Event Reporting System." Saudi Pharmaceutical Journal : SPJ : The Official Publication of the Saudi Pharmaceutical Society, vol. 31, no. 7, 2023, p. 1360, https://doi.org/10.1016/j.jsps.2023.05.023.